Hemolyzing solutions are used in capillary electrophoresis for haemoglobin analysis. Clinical laboratories are using haemoglobin electrophoresis for the screening of haemoglobin abnormalities. Haemoglobin electrophoresis is a very popular and well-established technique to detect a large number of haemoglobin variant. Hemolyzing solutions are used in haemoglobin electrophoresis for efficient separation and detection of haemoglobin variants. The haemoglobin disorders such as sickle cell anaemia, thalassemia syndromes etc. are the common inherited diseases results in death in the first few years of life. WHO has been conducted several workshops to estimate the global burden of thalassemia and different haemoglobin variants. There are above 300,000 annual birth of infants with serious forms of haemoglobin disorders has been reported by WHO. Thalassemia is frequent in some population throughout the Middle East, Southeast Asia and parts of Africa. Haemoglobin electrophoresis using hemolyzing solutions checks the different types of haemoglobin present in the blood that may be normal or abnormal. Haemoglobin A is the normal and most common type haemoglobin found in adults. Haemoglobin F is normally found in newborn babies and fetuses. Diseases such as sickle cell anaemia, leukaemia have a higher amount of haemoglobin F. There are more than 350 varieties of abnormal haemoglobin's are found in the human body. The most common type of abnormal haemoglobins is haemoglobin C and haemoglobin S, which may be found by electrophoresis test using hemolyzing solutions. Hemolizing solutions are used in electrophoresis for hemolysis of haemoglobin in blood samples. Electrophoresis separates normal and abnormal types of haemoglobin in the blood by using electrical current. Presence of abnormal haemoglobin types may cause mild diseases or diseases that can be life-threatening. However, hemolyzing solutions play a very important role in haemoglobin electrophoresis test. Doctors are usually prescribing haemoglobin electrophoresis test in case of complete blood test during a routine physical checkup for the diagnosis of blood disorders, to monitor treatment, to screen for genetic conditions etc.
The hemolyzing solutions market can be segmented by application, disease type and end-user.
Based on the application the hemolyzing solutions market can be segmented as
Based on the disease type the hemolyzing solutions market can be segmented as
Based on end-users the hemolyzing solutions market can be segmented as
Increasing prevalence of haemoglobin disorders such as sickle cell anaemia, thalassemia drives the hemolyzing solution market for the early detection of abnormal haemoglobin variants using capillary electrophoresis technique. The importance of using hemolyzing solutions in the electrophoresis technique for the detection of abnormal haemoglobin variants also drives the hemolyzing solutions market. Increasing incidents of haemoglobin abnormality due to genetic disorders also drives the market of hemolyzing solutions. The rising demand among the individuals for haemoglobin test drives the hemolyzing solutions market. However, due to the lack of awareness and risks of infection during blood haemoglobin test may restrain the market of hemolyzing solutions.
Haemoglobin abnormality causes various kinds of life-threatening diseases especially in the case of newborn babies around the world. Hemolyzing solutions are necessarily used in haemoglobin electrophoresis for the detection of abnormal haemoglobin which drives the market of hemolyzing solutions during forecast periods. Government and non-government organizations conducting various awareness programs for the treatment of haemoglobin diseases which will drive the hemolyzing solutions market during forecast periods. Increasing prevalence and incidences of sickle cell anaemia and thalassemia in the Middle East, Southeast Asia and parts of Africa will also provide growth to the hemolyzing solutions market.
North America is expected to share a large market of hemolyzing solutions due to the growing research activities on blood-related disease prevention and increasing focus on routine health checkup followed by Europe. Considerable market growth of hemolyzing solutions has also been expected from the Middle East, Asia Pacific and African countries due to the increasing prevalence of haemoglobin disorders. Prominent growth of hemolyzing solutions market has been expected from the emerging countries such as China, India, Brazil and South Africa in the forecast years which will provide a huge opportunity to lunch new product among the market players.
Some of the key players operating in the hemolyzing solutions market are EKF Diagnostics Holdings Plc., DiaSys Diagnostic Systems GmbH, Roche Holding AG among others.
The report covers exhaustive analysis on: